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We investigated  the  kinetics of the  inhibitory  action 
of antithrombin 111 and  antithrombin I11 plus heparin 
during  the  activation of factor X by factor IX,. Gen- 
eration  and  inactivation  curves  were  fitted  to a three- 
parameter two-exponentional model to  determine  the 
pseudo first-order rate constants of inhibition of factor 
IX, and  factor X, by antithrombin  III/heparin. In  the 
absence of heparin,  the second-order rate constant of 
inhibition of factor X, generated  by  factor IX, was 2.5- 
fold lower  than  the rate constant of inhibition of ex- 
ogenous factor X.. It appeared that phospholipid-bound 
factor X protected  factor X, from  inactivation by anti- 
thrombin 111. It is, as yet,  unclear  whether an active 
site or a nonactive site interaction between factor X, 
and  factor X at the phospholipid surface is involved. 
The  inactivation of factor IX, by antithrombin I11 was 
found to be very slow and  was not affected by phos- 
pholipid, calcium, and/or  factor X. With unfractionated 
heparin above 40 ng/ml and  antithrombin I11 at 200 
n M ,  the  apparent second-order rate constant of inhibi- 
tion of exogenous and  generated  factor X, were  the 
same. Thus, in this case phospholipid-bound factor X 
did not protect  factor X. from inhibition. In  the pres- 
ence of synthetic  pentasaccharide  heparin, however, 
phospholipid-bound factor X reduced the rate constant 
about &fold. Pentasaccharide had no effect on the 
factor IXJantithrombin 111 reaction. Unfractionated 
heparin (1 pg/ml) stimulated  the  antithrombin 111-de- 
pendent inhibition of factor IX, during  factor X acti- 
vation 400-fold. In  the absence of reaction components 
this  stimulation  was 65-fold. We established that cal- 
cium stimulated the heparin-dependent  inhibition of 
factor IX.. 
Antithrombin I11 (ATIII)’ is a plasma protein that plays an 
important role in the regulation of a series of activation 
reactions leading to clot formation (1). From studies with 
purified serine proteases and  inhibitor, it is well known that 
the main target of ATIII is thrombin, whereas the activity 
toward activated factor X and activated factor IX is less 
pronounced (2,3).  
Heparin accelerates the  rate  at which ATIII inactivates the 
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The abbreviations used  are: ATIII,  antithrombin 111; UFH, un- 
fractionated heparin; PS, phosphatidylserine; PC, phosphatidylcho- 
line. 
serine proteases of the blood coagulation system. Dependent 
on the molecular weight of the heparin preparation used, the 
rate enhancing effect of heparin on the inhibition of factor 
IX, and factor X, seems to vary (4). Inactivation of factor IXa 
was found to decrease with decreasing molecular weight, 
whereas the inhibition of factor X, was potentiated by low 
molecular weight heparin fractions that have virtually no 
effect on the inactivation of factor IX,. 
Factor X, is the common product of the intrinsic and 
extrinsic coagulation pathway. Its formation has been postu- 
lated to be an important  target  for the control of thrombin 
formation (5, 6). Furthermore, factor X, may play a role in 
the activation of factors V, VIII, and VI1 (7-9). Although the 
effect of ATIII  and AT111 plus heparin on isolated factor X, 
and factor IX, has been studied (10-13), little is known about 
the kinetics of inactivation of factor IX. and factor X. during 
factor X activation. 
Previous studies reported the effect of ATIII on factor X, 
generated by simple activators of factor X, such as  the factor 
X-activating protein from Russell’s viper venom (14). Re- 
cently Jesty (15) described the inhibition of in situ generated 
factor X. by ATIII. When using factor IX. as an activator of 
factor X, however, he could not accurately analyze overall 
factor X, generation and inactivation. This  author also did 
not  present kinetic parameters on the inactivation of factor 
X, generated by factor IX,. 
In  this paper we present  a method which  allows the simul- 
taneous analysis of the kinetics of both factor IX, and factor 
X, inactivation by ATIII  or  ATIII  plus heparin during factor 
X activation. By this approach we were able to assess the 
relative importance of factor IX, inhibition and factor X, 
inhibition to the overall effect of unfractionated heparin 
(UFH)  and synthetic pentasaccharide heparin  on factor X, 
generation. We report some marked differences between the 
kinetics of the inhibition reactions during factor X activation 
and those observed in the absence of factor X, phospholipid, 
and/or calcium. 
EXPERIMENTAL PROCEDURES 
Materiuk-The synthetic peptide substrates Bz-Ile-Glu-(Piperi- 
dyl)-GIy-Arg-p-nitro-anilide hydrochloride (S-2337) and H-D-Phen- 
ylalanyl-L-pipecolyl-L-arginine-p-nitroanilide dihydrochloride ( S -  
2238) were purchased from Kabi. Fatty acid-free ovalbumin was a 
product of Sigma. All reagents used were  of the highest grade com- 
mercially available. 
Unfractionated heparin (168 USP units/mg) was from Pharmuka 
Laboratories, France, and synthetic pentasaccharide heparin (800 
anti-factor X. units/mg and no anti-thrombin  activity) was a kind 
gift from Institut Choay, France. 
Proteins-Bovine ATIII was purified by the method of Thaler and 
Schmer (16). The ATIII was subsequently freed of heparin contami- 
nation by ion-exchange chromatography (17). All other bovine clot- 
ting factors were prepared and quantitated as previously described 
(18-20). 
15313 
 at UKB - Universiteit M
aastricht on August 3, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
15314 Factor X ,  Generation  and Inactivation 
Phospholipid Vesicles-Phospholipid vesicles were made from a 
mixture of phosphatidylserine (PS)  and phosphatidylcholine (PC) as 
previously described (20). Vesicles  composed of 25 mol % PS and 75 
mol % PC were used throughout the experiments unless stated 
otherwise. 
Determination of Inhibition Rate of Purified Protease-The inac- 
tivation of factor X. by ATIII was investigated under pseudo first- 
order conditions essentially as previously described (3). The inacti- 
vation of factor IX,  was  followed  by incubations by factor IX. with 
ATIII/heparin in the presence or absence of accessory components, 
and  at several time points residual factor IX. activity was assayed as 
described previously (21) with the following modifications. Factor 
1%-containing samples were diluted 1:lOOO into buffer containing 50 
mM Tris-HC1, pH 7.9, 175 mM NaCl, 0.5 mg  of ovalbumin/ml, 5 mM 
CaClz, 20 p~ phospholipid, and 100 nM thrombin, prewarmed at 
37 "C for 4 min. Factor V1II:C (10 units/ml) was added and allowed 
to be activated for 15 s, after which the reaction was started by the 
addition of factor X (0.5 p ~ ) .  The  rate of factor X activation was 
determined by measuring the amount of factor X, formed after 0.5 
and 1.5 min using the chromogenic substrate S2337 as described 
earlier (3). Factor X, formation was linear in time for at least 2 min. 
From the observed rate of factor X activation, the amount of factor 
IX. present  in the sample was calculated using a calibration curve 
made with known amounts of active site-titrated factor TX,. 
Inactivation of Factor IX. and Factor X ,  by ATIIIIHeparin during 
Factor X Activation-Factor X (1 pM) was activated by 80 nM factor 
IX., in the presence of 100 WM phospholipid, 10 mM CaC12 and heparin 
when indicated in 50 mM Tris-HC1, 175 mM NaCl and 0.5 mg/ml 
ovalbumin, pH 7.9, at 37 "C. At  timed intervals  after the addition of 
factor IX., aliquots (7 bl) were removed and assayed for factor X. 
activity. Factor X. formation was linear in time for at least 30 min. 
After 10 min an aliquot (200 J) was taken from the reaction mixture 
and added to  a solution (14 pl) containing ATIII and rabbit anti- 
factor IX IgG. At the same time another aliquot (200 pl) was taken 
from the reaction mixture and added to a solution (14 rl) containing 
ATIII alone. Addition of anti-factor IX resulted in  instantaneous and 
complete inhibition of factor X, formation but had no effect on factor 
X. activity or  on the ATIII/factor X. reaction. After the addition of 
ATIII or ATIII plus anti-factor  IX, timed samples (7  pl) were taken 
and assayed for factor X, activity. 
Because the rabbit  anti-factor IX IgG neutralized unfractionated 
heparin,  anti-factor IX IgG could not be used to block further factor 
X. formation to measure the effects of UFH on X, inhibition. There- 
fore, we modified the conditions for the determination of the effect 
of UFH on the inactivation of factor IX. and factor X, during factor 
X activation. Factor X was activated in the presence of UFH under 
the same conditions as described before. Factor X. formation was 
monitored by removing aliquots (7 111) and assayed for factor X, 
activity. After 10 min, 200 pl was removed and added to a solution of 
ATIII (14 pl). From this reaction mixture, timed samples (10 pl) were 
taken, and assayed for factor IX, activity as already described. From 
the same mixture, aliquots (7  rl) were taken  and assayed for factor 
X, activity. The pseudo first-order rate constants of inhibition of 
factor X. and factor IX,  were calculated as described in the following 
section. 
Kinetic Analysis of the Inhibition of Factor I X ,  and factor X, during 
Factor X Activation-Under the experimental conditions of our stud- 
ies, factor X. formation was linear during the time period of the 
experiment when ATIIl was absent. This was obtained by using 
factor X concentrations well  above the K,,, for factor X and less than 
20% of factor X consumed during the experiment. Secondly, the 
ATIII concentrations were in excess over the factor X, and factor 
IX. concentrations, resulting in pseudo first-order kinetics of inhibi- 
tion. 
When ATIII or ATIII plus heparin was present during the activa- 
tion of factor X by factor IX. we assumed that the amount of 
amidolytic active factor X. present at time t is a function of the rate 
of inactivation of factor IX, and  the rate of inactivation of factor X,. 
In formula this reads: 
d - [X.] = u e-k1xa1 - kxa [X,] 
dt (1) 
where v is the rate of factor X,, formation in the absence of ATIII or 
ATIII plus heparin, krx, and kxa are the pseudo first-order rate 
constants of inhibition of factor IX. and factor X,, respectively. 
Integration of Equation 1 by Laplace transformation gives the 
following equation for the generation of factor X, concomitant with 
its decay. 
[X.], = ___ 
kxa - klX. 
u (e-*Ixaf - e-hxa') (2) 
The parameters, u, krx, and kx,, could be determined by fitting 
Equation 2 to  the experimental data points. However, we preferred 
an analysis of our data which also allows independent  determinations 
of the parameters v and kx,. To  this end, the activation of factor X 
in the absence of ATIII was performed for to min, followed by the 
addition of ATIIl or ATIII plus anti-factor IX IgG. 
When ATIII is added at  time to, the factor X, concentration then 
obtained 
[Xal,=t0 = ut, (3) 
has to be included into Equation 2: 
[xa], - (e- i~~e(+fal  -e-*xact-tol 
kxa - klxa ) + [x~I,, e"Xa'L"o) (4) 
When ATIII plus anti-factor  IX IgG are added at  time to, factor X. 
formation is completely blocked but  not  the decay of factor X, and 
reduces Equation 4 to 
[Xa], = [XaIt=, e -k~Jl-co) (5) 
If t 5 to  then 
[X.L = ut  (6) 
Equations 4-6 were simultaneously fitted to experimental data points, 
obtained in the absence or presence of ATIII/heparin or in the 
presence of ATIII/heparin plus anti-factor IX I&. The  fit procedure, 
based upon a nonlinear least  squares regression method which uses a 
reiterative Gauss-Newton algorithm (22), produced u,  klx. and kx.. In 
addition, kxa and v were separately calculated using Equations 5 and 
6, respectively, to estimate the validity of the parameter values as 
calculated by the fit procedure. The reported errors represent the 
95% confidence interval, about twice the S.D. of the estimate. 
RESULTS 
Determination of Factor IX ,  and Factor X, inactivation by 
ATIII during Factor X Activation-Factor X was activated 
by factor IX, in the presence of phospholipid and calcium. 
After 10 min, to a part of the reaction mixture a solution of 
ATIII  and  rabbit  anti-factor IX IgG was added, and at  the 
same time AT111 alone was added to another part of the 
reaction mixture. The result of such a typical experiment is 
shown in Fig. 1. Curve A shows linear factor X, generation 
and addition of both  anti-factor IX IgG and ATIII at t = 10 
min resulted in  the exponential decay of the formed factor X, 
(curue C), whereas addition of ATIII alone resulted in signif- 
icantly higher residual factor X. activities because of ongoing 
factor X, generation (curue B) .  
Equations 4-6 (see "Experimental Procedures") were fitted 
to  the experimental data  and  the factor X, generation and 
inactivation curves, indicated by the solid  lines, are  the results 
of the best fit to  the  data points. The pseudo first-order rate 
constants of inactivation of factor X, and factor IX, by ATIII 
as well as  the velocity of factor X, formation in the absence 
of AT111 were obtained by the computer fit procedure. In  this 
typical experiment the velocity of factor X, formation ( u )  was 
found to be 2.1 +- 0.1 nM min-', whereas the pseudo first- 
order rate  constants ( k )  of inactivation of factor X, by ATIII 
(1 PM) was  0.21 5 0.01 min". However, the pseudo first-order 
rate  constant of inactivation of factor IX.  by AT111 was too 
small to  measure accurately (<O.OI rnin"). 
The calculated parameters u and k can also be determined 
directly from part A and  part C of the curves, respectively. 
The rate of factor X, formation was 2.1 nM/min (part A). The 
pseudo first-order  rate  constant of inactivation of factor X, 
by ATIII was determined from the semilogarithmic plot of 
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TIME ( m i d  
FIG. 1. Factor X. generation in the  presence of ATIII. Factor 
X (1 PM) was activated by 80 nM factor IX. in the presence of 100 
@M phospholipid  and 10 mM calcium (curve A ). At 10 min, to 200 p1 
of the reaction mixture, 1 p~ ATIII was added (curue B ) .  At the same 
time, to another 200 pl of the reaction  mixture 1 pM ATIII and anti- 
factor IX IgG was added (curue c). Factor X. activity was assayed as 
described  under  "Experimental  Procedures." The solid  lines represent 
factor X. generation and inactivation as calculated by the fit proce- 
dure. Inset, semi-logarithmic  replot of curve C. 
part C of the  curve uersus time, k k ,  = 0.21 min" (Fig. 1, inset). 
Thus, the independently determined values for the  rate of 
factor X activation  and  the  rate  constant of factor X, inacti- 
vation were the very same  as  the values from  the  fit-procedure, 
indicating  the validity of our  mathematical model. 
This procedure was repeated in the presence of various 
ATIII concentrations (0-1.5 pM) .  A linear relationship be- 
tween the  pseudo  first-order  rate  constants of inhibition of 
factor X, and  the  ATIII  concentration was  found. The second- 
order rate constant was 2.1 +- 0.1 X lo5 "' min". The 
inactivation of factor IX, during  factor X activation at  the 
ATIII  concentrations used was too  small ( k ~ x ,  < 0.010 rnin") 
to  be measured accurately.  Higher  ATIII  concentrations, how- 
ever,  could not  be  used  under  these  conditions because then 
the  factor X, generated by factor IX. was too rapidly inacti- 
vated  and  resulted  in very low residual factor X, activities. 
In  order  to  determine  the  inactivation of factor IX. at  higher 
ATIII  concentrations we made use of a factor IX, assay  in 
which functional  factor IX, activity  was  determined via the 
factor VII1,-enhanced activation of factor X  (see "Experimen- 
tal Procedures"). The pseudo first-order rate constants of 
factor IX, inactivation by ATIII  in  the  presence of factor  X, 
phospholipid, and calcium were plotted uersus the ATIII 
concentration (0-10 p ~ ) .  A  second order-rate  constant of 8.2 
X lo3 M" min" was calculated. In  the  absence of the  reaction 
components (factor X, phospholipid, and Ca2+) the second- 
order  rate  constant of factor IX, inactivation was found  to be 
the  same  as in their  presence (k2  = 8.2 X lo3 M" min"). 
Effect of Accessory Components on  Factor X ,  Inactivation 
by ATIZZ-As several investigators reported contradictory 
effects of phospholipid or calcium (23-27) on  the  inactivation 
of factor X, by ATIII, we examined  whether  our decay con- 
stants,  determined by the  fit-procedure  during  factor X acti- 
vation, differed  from the decay constants of factor X, in free 
solution. 
To  this  end, we incubated purified factor X, (10 nM) with 
AT111 (0-1.5 p ~ ) ,  either  in  the  absence or presence of phos- 
pholipid (100 p ~ ) ,  calcium (10 mM), or both. The second- 
order  rate  constant of inhibition of factor X, by ATIII in  free 
solution was 5.0 X lo5 M" rnin", and  neither  the  addition of 
phospholipid or calcium or phospholipid plus calcium pro- 
tected  factor X, from  being inactivated by ATIII.  Under  all 
conditions  the  rate  constants were 5.0 k 0.1 X lo5 M" min". 
However, these  rates of inactivation of factor X, appeared  to 
be  still  about 2.5-fold faster when compared  to  the  rates of 
inactivation  under  the  conditions of factor X activation (see 
previous section). In order to find an explanation for this 
discrepancy, we added, besides phospholipid and calcium, 
factor X (1 p ~ )  to  the  inactivation  mixture.  The  second-order 
rate  constant of 2.1 X io5 M-' min" for factor X. inactivation 
by ATIII  thus  obtained, was the  same  as  determined  during 
factor X activation. 
These  results suggest that  the decrease of the  second-order 
rate  constant of the  factor X.-ATIII reaction  during  factor X 
activation  is  due  to  the  presence of phospholipid-bound  factor 
X. Indeed,  the pseudo first-order  rate  constant of inhibition 
of factor X. in  the  presence of a fixed phospholipid concen- 
tration decreased  with increasing  factor X concentration (Fig. 
M).  In  addition,  an increase of the phospholipid concentra- 
tion at a fixed factor X concentration  resulted  in a  decrease 
of the  rate  constant (Fig. 2 B ) .  In  both  cases  the  rate  constant 
progressively decreased to  an  apparent  end value of 0.2 rnin". 
It  has  been  reported  that bovine factor X can  be  converted 
by factor X, into  0-factor  X,  factor X,, and/or ,&factor X, 
(28-30). In  the  presence of phospholipid  the major reaction 
product appeared to be 0-factor X (30). An exponentional 
increase  in  factor X, generation  as a result of the  autocatalytic 
activation of factor X by factor X. might  explain  the  apparent 
lower pseudo first-order  rate  constant of inactivation of factor 
X, in  the  presence of phospholipid-bound  factor X. However, 
under  none of our  experimental  conditions could an  increase 
in amidolytic factor X, activity be detected. In addition, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 
samples taken from a mixture containing 10 nM factor x., 
200 p~ phospholipid, 10 mM cazS, and 5 pM of factor x 
revealed the formation of 0-factor X at a very slow rate. 
Under  the  same  conditions  but  in  the  absence of phospholipid, 
no cleavage of factor X was observed over a 1-h period. 
In  order  to explore the effect of phospholipid-bound  factor 
X in more detail the following experiment was performed. 
Pseudo  first-order  rate  constants of inactivation of factor X, 
(10 nM) by ATIII (1 p ~ )  were determined  in  the  presence of 
factor x (10 pM), ca2+ (10 mM) and varying concentrations 
of phospholipid  composed of 10 mol % PS, 90 mol % PC, or 
A 0 1 
0.0 1 1 1 . .  . 4 . I  
0.0 0.4 0.8 1.2 0 25 50 75 100 125 
[FACTOR x], p~ [PHOSPHOUPID]. pM 
FIG. 2. Effect of factor X and phospholipid on the  inacti- 
vation of factor X, by ATIII. Panel A ,  factor X. (10 nM) was 
incubated with ATIII (1 p ~ )  in the presence of varying amounts of 
factor X, Ca2+ (10 mM) and 100 p~ phospholipid (0) or in the absence 
of phospholipid (0). Panel B, the same incubation but in the presence 
of varying amounts of phospholipid, Ca2+ (10 mM) and 1 pM factor X 
(0) or in the absence of factor X (0). The pseudo first-order rate 
constants of inactivation of factor X. by ATIII were determined as 
described under  "Experimental  Procedures." 
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25  mol % PS, 75 mol % PC. The rate  constants progressively 
decreased until  apparent  end levels of 0.1 and 0.3 min" in 
the presence of vesicles containing 25  mol % PS or 10 mol % 
PS, respectively (Fig. 3). From reported factor X-phospho- 
lipid-binding parameters (31, 32) it was calculated that at 
each phospholipid concentration used, virtually all available 
phospholipid-binding sites were saturated with factor X, i.e. 
12.3  pmol of factor X bound/mmol of 25% PS, 75% PC and 
6.7 pmol factor X bound/mmol of 10% PS, 90% PC. Thus, 
the fraction of factor X bound to phospholipid linearly in- 
creased with the phospholipid concentration. Although factor 
X  and factor X, interact competitively with the same phos- 
pholipid-binding sites, factor X, by virtue of its affinity for 
phospholipid and factor X,, promotes the binding of factor 
X. at  the surface. Hence, an apparent inhibition of the inac- 
tivation reaction might be a consequence of a decreased fluid- 
phase factor X. concentration concomitant with an increase 
in  the concentration of phospholipid-bound factor X.  Addi- 
tional support for our notion that the factor X,-factor X 
association rate at  the surface might be the controlling ele- 
ment was obtained from an identical set of experiments but 
using a  nonsaturating factor X  concentration (0.2 pM). The 
observed rate constant of the inactivation reaction went 
through  a minimum of  0.4  min" at 60 p~ phospholipid (25% 
PS, 75% PC)  and  then increased with further increase in  the 
concentration of the phospholipid until an almost nonin- 
hibited value (0.55 min") at 400 pM of phospholipid. 
Effect of Unfractionated Heparin  and Pentasaccharide on 
Factor ZX, and Factor X. Inactivation by A TZIZ during Factor 
X Actiuation-For the determination of the pseudo first-order 
reaction rate  constants of factor IX. and factor X, inactiva- 
tion during factor X activation by ATIII (200 nM) in the 
presence of UFH (0-120 ng/ml) or pentasaccharide (0-12  ng/ 
ml), the same fit-procedure as already described was used. 
However, as the rabbit anti-factor 1X IgG neutralized the 
UFH, but  not pentasaccharide, we modified the conditions 
for the investigation of the effect of UFH.  Instead of blocking 
the factor IX, activity by the addition of anti-factor  IX IgG, 
ATIII only was added, and factor IX, inactivation was deter- 
mined separately as described under "Experimental Proce- 
dures." In order to obtain the decay constant of factor X. 
generated by factor IX., Equations 1-4 were fitted to the 
experimental data with the parameters Vxa and k ~ x ,  set at 
values calculated from direct measurements according to 
Equation 6 and  to [1X,It = [IX& exp(-k,x&), respectively. 
Our mathematical model for analysis of the  data depends 
0.0 ' 
0 100 200 300 400 
[Phospholipid], pM 
FIG. 3. Effect of factor X and phospholipids of different 
compositions on the inactivation of factor X, by antithrombin 
111. Factor X, (10 nM) was incubated with ATIII (1 WM) in the 
presence of factor x (10 FM), calcium (10 mM), and varying concen- 
trations of phospholipid vesicles  composed of 10 mol % PS, 90 mol 
% PC (A), or 25 mol % PS, 75 mol % PC (0). 
on heparin-dependent  factor X, and factor IX, inactivation 
being a pseudo first-order reaction. This approach will only 
work if the protease concentrations remain far below satura- 
tion levels (1). Therefore, pseudo first-order rate constants 
had to be determined as  a function of the protease concentra- 
tion under the same experimental conditions. To  this end, 
factor IX. at different concentrations (40 and 80 nM) was 
incubated with ATIII (200 nM) and heparin (300 ng/ml) in 
50 mM tris-HCl, pH 7.9, 175 mM NaC1, 5 mM CaC12, and 0.5 
mg ovalbumin/ml. Linear first-order  rate  plots were obtained 
for at least 70% of the reaction. Rate  constants f S.E. were 
calculated from a linear least-squares fit using six time points 
in  triplicate to be 0.203 k 0.017 min-l (40 nM factor IX.) and 
0.213 f 0.011 min" (80 nM factor IX,). We concluded that 
the  apparent pseudo first-order  rate  constant of inhibition of 
factor IX, under our conditions and within the range used 
was independent of the factor IX. concentration. This finding 
also holds for the inactivation of factor X,  by ATIII (200 nM) 
in the presence of heparin (80 ng/ml). The rate constants 
were  0.756 f 0.033  min" (10 nM factor X.) and 0.759 f 0.039 
min" (20 nM factor x,). 
Fig. 4 shows the effect of UFH  and  pentasaccharide on the 
inactivation of factor X,  by ATIII, both for free solution and 
for factor X, during factor X activation. The stimulating 
effect of UFH on the inactivation of purified factor X, by 
ATIII (Fig. 4A) was the same either  in the presence or in the 
absence of phospholipids and/or calcium, with a  rate  constant 
of 0.012  min"  (ng/ml)".  However, during factor X activation 
the inhibition of factor X, generated by factor IX,  was mark- 
edly reduced at heparin concentrations up to 40 ng/ml. At 
higher UFH concentrations the stimulating effect was the 
same as observed with purified factor X, in free solution. 
Because this phenomenon was also observed in the presence 
of factor X alone, it might indicate that factor X and ATIII 
compete with each other for UFH. Indeed, when increasing 
amounts of factor X were added to a mixture containing 
factor X. (10  nM), ATIII (200 nM), and 40 ng  of UFH/ml, the 
rate  constant of the inactivation reaction progressively de- 
creased with increasing factor X eventually reaching the value 
of the heparin-independent ATIII-X, reaction. The factor X 
concentration that neutralized half the amount of available 
UFH was 0.2 p ~ .  
The stimulating effect of pentasaccharide  on the inactiva- 
tion of factor X. by ATIII was 5-fold lower during factor X 
activation as compared to factor X, inactivation in free solu- 
tion (Fig. 4B). The  rate  constants were 0.014  min" (ng/ml)" 
and 0.071 min" (ng/ml)", respectively. Factor  X alone did 
not have an effect on the pentasaccharide-dependent inacti- 
vation of factor X,. Thus, the lower rate constant during 
0 
"i 3 6 9 1 2  
[PENTAUCCHARIDE]. ng/rnl 
factor X. by ATIII as a function of the UFH (panel A )  and the 
FIG. 4. Pseudo first-order rate constants of inactivation of 
pentasaccharide (panel E )  concentration. 0, factor x. (10 nM) 
plus ATIII (200 nM) and A, factor X. during factor X activation by 
[factor IX.-phospholipid-Ca2+] in the presence of ATIII (200 nM). 
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Frc. 5. Pseudo first-order  rate constants of inactivation of 
factor IX. (80 nM) by ATIII (200 n M )  as a function of the UFH 
concentration. 0, factor IX, alone; 0, factor IX. during factor X 
activation; and A, factor IX. in the presence of calcium (10 mM). 
factor X activation was the result of the protective effect of 
phospholipid-bound factor X on the inactivation of factor X.. 
Pentasaccharide was unable to enhance the inactivation of 
factor IX., either in the absence or presence of calcium, 
phospholipid, and/or factor X.  Fig. 5 shows that  UFH had  a 
very small effect on the inactivation of factor IX. in free 
solution, k = 0.11  min"  (pg/ml)".  However, during factor X 
activation a 6-fold higher rate constant of inactivation of 
factor IXa was found, k = 0.68  min" (pg/ml)-'. To establish 
the cause of this discrepancy, we examined the effect of UFH 
on factor IX. inactivation  in the presence of the individual 
components present in the factor X activation mixture. From 
Fig. 5 it is clear that  the enhanced inactivation rate of factor 
IX.  by ATIII is solely due to  the presence of calcium. 
DISCUSSION 
Several investigators have studied the inactivation of acti- 
vated coagulation factors IX  and  X by ATIII (10-13).  How- 
ever, the majority of these studies dealt with the effect of 
ATIII on purified factor IX, and factor X. in free solution. 
In the present paper we describe a method for the deter- 
mination of decay constants under more  physiological condi- 
tions by modeling the inactivation of factor IX. and factor X, 
during factor X activation. The validity of this model was 
confirmed by the close resemblance between the  data com- 
puted by the fit-procedure and  the experimentally obtained 
data points (Fig. 1). Furthermore,  our experimental approach 
provided independent control of the velocity of factor X, 
formation and  the  rate of inactivation of generated factor X,. 
These values were in good agreement with the values as 
determined by the fit-procedure. 
The second-order rate  constant for factor X, inactivation 
by ATIII thus obtained was  2.1 X lo5 M" min". Because of 
the much lower rate of inhibition of factor IX, under these 
conditions when compared with factor X,,  we were unable to 
calculate the rate  constant of inhibition of factor IX,  by ATIII. 
However, by making use of a factor IX, assay and high ATIII 
concentrations, we found that  the reaction of factor IX, and 
ATIII proceeded with a second-order rate  constant of 8.2 X 
lo3 M" rnin", about 25-fold  slower  when compared with the 
factor X,/ATIII reaction. 
As several authors have reported that human factor X. (25) 
and bovine factor X. (26) are protected from inactivation by 
ATIII in the presence of phospholipids, we compared the 
decay constant of factor X, determined during factor X  acti- 
vation with the decay constant of free factor X,. Indeed, we 
found that  the second-order rate  constant of factor X. inac- 
tivation by ATIII was 5.0 X lo5 M" min", compared to a 
second-order rate constant of 2.1 X lo5 M" min" during 
factor X activation. However, in  contrast to Ellis et al. (24) 
and Walker and Esmon (26),  but in accordance with Marci- 
niak (27)  and  Jesty  (15), we did not observe that factor X. 
was protected from inhibition by phospholipids. Using previ- 
ously reported binding data of the factor X(.,-phospholipid 
interaction (31, 32), it can be calculated that in the presence 
of 100 p~ of phospholipid (25 mol % phosphatidylserine, 75 
mol % phosphatidylcholine) 90% of total factor X, (10 nM) is 
bound to  the phospholipid surface, and, yet, the pseudo first- 
order rate  constant of inhibition of factor X, is the same as 
that in the absence of phospholipid (Fig. 2). Therefore, the 
presence of phospholipid does not explain the lower decay 
constant of factor X. during factor X  activation. Surprisingly, 
factor X appeared to reduce the  rate of the factor X./ATIII 
reaction. This phenomenon was only observed when both 
calcium and phospholipid were present. The similar effects of 
either increasing amounts of phospholipid at a fixed factor X 
concentration or increasing factor X at a fixed phospholipid 
concentration on the decay constant of factor X. strongly 
suggest that phospholipid-bound factor X protected factor X, 
from inhibition (Fig. 2). 
In view  of a factor X,-catalyzed conversion of phospholipid- 
bound factor X to P-factor X (28-30) it seems reasonable to 
rationalize the observed inhibition of the inactivation reaction 
in terms of a competitive enzyme substrate  interaction.  Thus, 
the rate constant of the ATIII-factor X, reaction will be 
attenuated by a factor of 1/( 1 + [ S]/K,,,) and should approach 
zero at saturating  substrate levels (33). However, a  substantial 
increase in surface-bound factor X did not result in  a  further 
decrease of the  apparent  rate  constant when factor X. was 
quantitatively bound to  the surface (Fig. 3). Moreover, the 
level to which the inactivation reaction could be inhibited 
appeared to be a function of the phosphatidylserine content 
of the phospholipid vesicle. Because the binding capacity of 
vesicles increases with increasing phosphatidylserine content 
(31) it seems that the local factor X concentration at the 
surface, rather  than  the bulk phospholipid-bound factor X 
concentration, is the effective substrate  concentration for the 
competitive reaction. 
At  present, an alternative mechanism, in which the active 
site of factor X, is not involved in the factor X.-factor X 
interaction at  the surface, can  not be ruled out. That is, the 
decrease in the  rate of inactivation of factor X. could also 
reflect a reduced reactivity of factor X, in the ternary complex 
of factor X-phospholipid-factor X, toward ATIII. 
The inactivation of factor IX, was not affected by the 
accessory components (phospholipid, calcium) and factor X. 
Regardless of the presence of factor X, phospholipids, and/or 
calcium, the second-order rate  constant for factor IX, inacti- 
vation by ATIII was 8.2 X lo3 M" min". In view of the 
protection of factor X,  by phospholipid-bound factor X, it is 
quite striking that the interaction between factor IX. and 
factor X at the surface does not compete with the ATIII- 
factor IX, reaction. However, because the phospholipid-factor 
IX, interaction would  be one of the affecting elements, it is 
interesting to note that  the binding constant of this  interac- 
tion is substantially larger than  the one reported for the factor 
X,-phospholipid interaction  (34). 
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We next examined the effect of two types of heparin,  UFH, 
and  synthetic  pentasaccharide  heparin, on the inhibition of 
factor IX, and factor X, during factor X activation. Penta- 
saccharide was included in our study because of reported 
effects of the non-ATIII-binding region of heparin molecules 
on factor X, (25) and factor IX. inhibition (13). 
Comparing the inhibition of factor X, during factor X 
activation  in the presence of UFH  and pentasaccharide, it is 
evident that a polysaccharide sequence in addition to the 
ATIII-binding sequence alters the kinetics of factor X, inhi- 
bition in such a way that  it diminishes the protection of factor 
X, by phospholipid-bound factor X. It is feasible that  the 
competitive interaction between factor X. and phospholipid- 
bound factor X is counterbalanced more strongly by the 
interaction between factor X. and UFH-ATIII because of the 
higher affinity of factor X, for UFH-ATIII than for pentasac- 
charide-ATIII. 
Pentasaccharide could not  enhance the inhibition of factor 
IX, by ATIII. Apparently, factor 1X.-binding regions on the 
heparin molecule are absolutely required for its catalytic 
function. The decay constant of factor IX. increased linear 
with the concentration of UFH, k = 0.65 min”/pg of UFH/ 
ml. To our surprise, the stimulatory effect of UFH on the 
inactivation of factor IX, was about 6-fold higher during 
factor X activation as in free solution. It appeared that  this 
stimulation was due to  the presence of calcium (Fig. 5). The 
same phenomenon has been reported for human factor X, 
(25). Calcium, because of its ability to induce structural 
changes in factor IX. (35, 36), may affect the heparin-cata- 
lyzed reaction either by enhancing ternary complex formation 
or by increasing the intrinsic  rate  constant of the ATIII-factor 
IX, reaction at  the heparin surface. 
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